Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: Cobicistat/elvitegravir/emtricitabine/TAF; Cobicistat/emtricitabine/elvitegravir/tenofovir-alafenamide; E/C/F/TAF; Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Elvitegravir/emtricitabine/tenofovir-alafenamide/cobicistat; Emtricitabine/cobicistat/elvitegravir/tenofovir alafenamide; Emtricitabine/tenofovir-alafenamide/cobicistat/elvitegravir; Genvoya; Tenofovir alafenamide/cobicistat/elvitegravir/emtricitabine; Tenofovir-alafenamide/elvitegravir/emtricitabine/cobicistat

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV integrase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 Apr 2020 Gilead Sciences completes a phase III trial for HIV-1 infections (treatment-experienced, in adults) in USA, Sweden, Belgium, Germany, Italy, Netherlands, Austria, Denmark, Portugal, Australia, Brazil, Canada, Dominican Republic, France, Mexico, Switzerland, Thailand, Puerto Rico, Spain and United Kingdom (EudraCT2012-005114-20) (NCT01815736)
  • 15 Oct 2019 Gilead Sciences completes a phase IIIb trial in HIV-1 infections (Treatment-experienced) in Austria, France, Germany, United Kingdom and USA (EudraCT2015-002713-30) (NCT02600819)
  • 02 Oct 2019 Efficacy data from a phase IIb trial in HIV-1 infections presented at the ID Week (IDW-2019)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top